Better Practice: Trimodality Treatment, 3x Improvement in Stage 3 Non Small Cell Lung Cancer (NSCLC)

Introduction Every year, there will be a certain treatment that will be the highlight of discussion and presentations in every oncology meetings/ events. Last year, it was durvalumab, which delivered superior results for a subgroup of non-small cell lung cancer (NSCLC) Addition of immunotherapy, durvalumab, to chemotherapy and radiotherapy treatment in stage 3 lung cancer…… Continue reading Better Practice: Trimodality Treatment, 3x Improvement in Stage 3 Non Small Cell Lung Cancer (NSCLC)

Stage 4 Lung Cancer: Targeted therapy & Immunotherapy. Which to Start?

Not all lung cancers are the same type. Not all lung cancers are of same stage. Not all lung cancers are treated with similar treatment. Targeted therapy For stage 4 lung adenocarcinoma (subset of NSCLC), further testing of EFGR and EML4-ALK mutation are routinely done in Malaysia. ROS1 rearranged mutation drivers is not routinely done…… Continue reading Stage 4 Lung Cancer: Targeted therapy & Immunotherapy. Which to Start?